Novartis and Roche/Genentech are facing a combined 444 million euros in fines from the French Competition Authority for “abusive practices” intended to sustain sales of an expensive product, according to a press release.
Genentech markets both Avastin and Lucentis in the U.S., while Roche markets Avastin and Novartis markets Lucentis outside the U.S. Novartis began marketing Lucentis in France in 2007 for treatment of age-related macular degeneration, at which time each injection cost 1,161 euros. Avastin is 30 times cheaper, the release said.
Novartis is being fined 385,103,250
Uncategorized